OncoMatch/Clinical Trials/NCT05394285
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer
Is NCT05394285 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Hetrombopag for breast cancer.
Treatment: Hetrombopag — This study now plans to explore the efficacy and safety of hetrombopag in cancer therapy-induced thrombocytopenia in advanced breast cancer, so as to further guide the clinical application of hetrombopag in chemotherapy-induced platelets.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy (lobaplatin, carboplatin, cisplatin) — current
must be platinum-containing chemotherapy regimen: lobaplatin, carboplatin, cisplatin, etc.
Cannot have received: thrombopoietin receptor agonist (Eltrombopag, Romigrastim)
Received thrombopoietin receptor agonist drugs (such as Eltrombopag, Romigrastim), or recombinant human thrombopoietin (rhTPO), recombinant human interleukin-11 (rhIL-11) within 1 month before screening
Cannot have received: recombinant human thrombopoietin (rhTPO)
Received thrombopoietin receptor agonist drugs (such as Eltrombopag, Romigrastim), or recombinant human thrombopoietin (rhTPO), recombinant human interleukin-11 (rhIL-11) within 1 month before screening
Cannot have received: recombinant human interleukin-11 (rhIL-11)
Received thrombopoietin receptor agonist drugs (such as Eltrombopag, Romigrastim), or recombinant human thrombopoietin (rhTPO), recombinant human interleukin-11 (rhIL-11) within 1 month before screening
Cannot have received: platelet transfusion
Received platelet transfusion within 3 days before randomization
Cannot have received: radiation therapy
Those who received simultaneous radiotherapy and those who received pelvic radiotherapy in the past
Lab requirements
Blood counts
Neutrophil count ≥ 1.0×10^9/L, hemoglobin ≥ 80g/L before administration of Haitrombopag
Kidney function
serum creatinine ≥ 1.5ULN or eGFR ≤ 60 ml/min (Cockcroft-Gault formula) [excluded]
Liver function
patients without liver metastases, ALT/AST>3ULN, TBIL>3ULN; patients with liver metastases, ALT/AST≥5ULN, TBIL≥5ULN [excluded]
The main organ functions are normal, and there are no serious complications. Neutrophil count ≥ 1.0×10^9/L, hemoglobin ≥ 80g/L before administration of Haitrombopag; Obvious abnormal liver function: patients without liver metastases, ALT/AST>3ULN, TBIL>3ULN; patients with liver metastases, ALT/AST≥5ULN, TBIL≥5ULN; Abnormal renal function: serum creatinine ≥ 1.5ULN or eGFR ≤ 60 ml/min (Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify